Roundup: Singaporean medical startup Oncoshot scores funding for India expansion, Australia and more instructions


Oncoshot receives funding to expand further in India, Australia

Singaporean medical startup Oncoshot has scored an undisclosed investment through a pre-Series A funding round led by Biofurmis and investor MassMutual Ventures.

Based on a press release, the financing will support the company’s further expansion into India and Australia.

There are four hospital networks in India and some networks of more than 20 hospitals in Oceania that are about to establish their respective national public-private clinical trial ecosystems, such as that of Singapore. Project EIS. The latter uses Oncoshot’s clinical trial matching platform to connect cancer patients, healthcare professionals, and pharmaceutical and biotechnology companies.

It is said that clinical trials worldwide lose about $35 billion each year due to inefficient processes in cancer research and patient recruitment.

Oncoshot has developed a solution to such problems by improving the medical records of clinical partners through AI and machine learning. The federated data system securely hosts critical and sensitive patient data within hospital buildings, providing hospital administrators with complete protection, access, and control over analytics and insights.

Health knowledge website Happiest Health goes live in India

Indian IT services and consulting firm Happiest Minds Technologies has launched a new online repository of health and wellness knowledge and information.

The website, called Happiest Health, aims to provide “in-depth, credible and reliable” information about health and wellness, according to a press statement.

It will inform its public about health and wellness breakthroughs and developments, drawn from new research and studies from global partner institutes. The portal will also showcase new early diagnosis tools, as well as user stories and comments.

In addition, a panel of physicians and wellness experts will contribute guest essays and articles that provide unique perspectives and interesting medical experiences.

“Through Happiest Health, we want to advance the importance of integrated medicine, deliver valuable knowledge through experts on early diagnosis and evidence-based therapies, and we do it with empathy and passion,” said Happiest Health President Ashok Soota.

Next year, the website will publish written and video content in regional languages ​​to cater to lower towns in India. Happiest Health will also be launching a podcast, web series and audio content soon.

Clinical trials in India confirm the effectiveness of AI in detecting referable glaucoma

Indian medical device manufacturer Remidio Innovative Solutions has reported positive results from separate clinical trials of its AI solution in detecting referable glaucoma.

Remidio offers an integrated screening solution for referable glaucoma, a stage in which the disease can be controlled even better through treatment. It consists of a fundus on the phone, a retinal imaging device and an AI algorithm for offline inference. The Medios Referable Glaucoma AI detects structural changes in the head of the optic nerve and the surrounding nerve fiber layer of the retina.

According to a press release, the entire detection process only takes 15 seconds.

The company recently partnered with two local eye hospitals, Aravind Eye Hospital in Pondicherry and Narayana Nethralaya (NN) in Bangalore, to test its screening solution.

In the clinical trial at NN, the AI ​​algorithm was shown to achieve a high sensitivity of 93.5% and a high specificity of 85.4% in detecting referable glaucoma, while early results from the clinical trial at Aravind showed that the algorithm also high sensitivity and specificity of 91.3% and 91.67%, respectively.

The company noted that while there are treatment options for treating referable glaucoma, simple screening tests are hard to come by. Today, glaucoma specialists continue to conduct a series of complex studies using multiple devices to detect referable glaucoma.

“Promising results show that our AI can enable health professionals and general ophthalmologists to make an objective screening diagnosis, especially in centers that lack advanced diagnostic equipment,” said Dr. Divya Rao, Medical Director and Head of AI at Remidio.